Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Kailera Therapeutics, Inc. (KLRA) had Stock-Based Compensation of $12.28M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-111.31M |
|
-- |
|
-- |
|
$121.37M |
|
$-121.37M |
|
$10.07M |
|
$-111.31M |
|
$-111.31M |
|
$-111.31M |
|
$-111.31M |
|
$-111.31M |
|
$-111.31M |
|
$-121.37M |
|
$-121.27M |
|
102.23M |
|
102.23M |
|
$-1.09 |
|
$-1.09 |
|
| Balance Sheet Financials | |
$929.17M |
|
$1.75M |
|
$282.25M |
|
$1.21B |
|
$83.65M |
|
-- |
|
$9.30M |
|
$92.95M |
|
$1.12B |
|
$1.12B |
|
$1.12B |
|
129.62M |
|
| Cash Flow Statement Financials | |
$-145.84M |
|
$-548.17M |
|
$664.05M |
|
$161.03M |
|
$131.06M |
|
$-29.97M |
|
|
Stock-Based Compensation |
$12.28M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-145.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.95% |
|
-9.95% |
|
-9.19% |
|
-9.95% |
|
$8.63 |
|
$-1.43 |
|
$-1.43 |
|